Ms. Humera Sarwar
School of Pharmacy and Pharmaceutical Sciences, University of Ulster, Coleraine, UK
+1
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
14Years (2013-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications
Journal Article
ESElliot Simpson
Elliot SimpsonHumera SarwarIJIain Jack
Iain JackDLDeborah Lowry
Deborah LowryChitosan nanoparticle delivery systems have the potential for enhancing bone healing and addressing osteomyelitis. The objective was to deliver antimicrobial agents capable of preventing or treating osteomyelitis. Each formulation was optimized to achieve desired characteristics in terms of size (ranging from 100 to 400 nm), PDI (less than 0.5), zeta potential (typically negative), and in vitro release profiles for gentamicin. Entrapment percentages varied with gentamicin ranging from 10% to 65%. The chitosan nanoparticles exhibited substantial antimicrobial efficacy, particularly against P. aeruginosa and MRSA, with zones of inhibition ranging from 13 to 24 mm and a complete reduction in colony forming units observed between 3 and 24 h. These chitosan nanoparticle formulations loaded with antimicrobials hold promise for addressing orthopedic complications.
11 March 2020
Book Chapter
IYishrat younus
ishrat younusSMSidra Maqbool
Sidra MaqboolSKSarah Jameel Khan
Sarah Jameel Khan
Humera SarwarSNShagufta Nesar
Shagufta Nesar
MBMoona Baig
Moona Baig
+2
Foot-and-mouth disease (FMD) is a contagious viral infection which is caused by foot-and-mouth disease virus (FMDV). The disease appears in cloven-footed animals. Symptoms of the disease are abrupt manifestation of sores on the mouth, nose, feet, etc. Nowadays the control and treatment of FMDVare becoming a worldwide economic problem and challenge for the society. Currently, there is no particular treatment available for FMDV, as well as the limitations and disadvantages in the use of vaccines divert the focus of researchers toward natural sources like plant extracts which possess potential antiviral activity. Various researches documented in the literature demonstrated various plant extracts with antiviral potency against FMDV. In the current chapter, we discussed about FMDV and its possible treatment with plant extracts.
30 June 2020 in Bulletin of Pharmaceutical Sciences. Assiut
Journal Article
RKRida Khalid
Rida Khalid
MNMuhammad Iqbal Nasiri
Muhammad Iqbal Nasiri
Humera SarwarRYRiffat Yasmin
Riffat Yasmin
KZKamran Zaheer
Kamran Zaheer
AFAnab Fatima
Anab Fatima
+1
The objectives of the current study were to investigate the influence of different types and concentration of polymers on release of ciprofloxacin HCl as well as to formulate an extended release tablets of ciprofloxacin hydrochloride by direct compression method. Twelve formulations (F1–F12) were manually designed using different proportions (10–30%) of Hydroxypropyl methylcellulose (HPMC), Ethylcellulose (EC) and Kollidon SR polymers. Avicel PH101, talc and magnesium stearate were used in a constant quantity of 2% in all the formulations. Multiple point dissolution was carried out in different media. Dissolution profiles indicated that formulations F1, F4, F8 and F11, extended the drug release up to 12 hrs, while, other formulations failed to retard the drug release up to desired period. DDSolver software was used to analyze the dissolution profile data for drug release kinetics such as first order, Zero-order, Korsmeyer–Peppas and Higuchi models. Drug polymers compatibility was assessed using Fourier Transformed Infrared (FTIR) spectroscopy. Selected formulations were placed in the stability chamber at accelerated temperature (40±2°C and RH 75±5%) for six months and re-evaluated after 3 and 6 months as per ICH guidelines. The present study accomplished that ethylcellulose alone or in combination with HPMC was found to be an excellent rate controlling agent for ciprofloxacin and may be used successfully to develop extended release tablet formulations.
1 March 2018 in International Journal of Endorsing Health Science Research (IJEHSR)
Journal Article
ASAdnan Zia Shamsi
Adnan Zia Shamsi
STSumbul Tasneem
Sumbul Tasneem
IHIqra Haider
Iqra Haider
MAMah Rukh Aslam
Mah Rukh Aslam
Humera Sarwar1 May 2021
Journal Article
SSSyed Suffdar Hussain Shah
Syed Suffdar Hussain Shah
MNMuhammad Iqbal Nasiri
Muhammad Iqbal NasiriHumera SarwarAAAatka Ali
Aatka Ali
SNSyed Baqir S. Naqvi
Syed Baqir S. Naqvi
MKMuhammad Kashif
Muhammad Kashif
+1
Daclatasvir dihydrochloride is an antiviral drug used in the treatment of Hepatitis C and for its estimation in drug product, no Pharmacopeial method is available. Therefore, a simple, rapid, precise and accurate isocratic RP-HPLC method was developed and validated for quantification of daclatasvir dihydrochloride in pharmaceutical dosage form. The quantification was carried out using Hypersil ODS - C18 Column (250mm, 4.6mm, 5 mu m), Shimadzu LC-2030 Prominence-I Series. The mobile phase composed of phosphate buffer (pH 3.5, adjusted with ortho phosphoric acid) and acetonitrile (60:40 v/v). The flow rate was 1.0ml/min with UV detection at 308 nm. The validation of developed method was conducted for specificity, linearity, accuracy, precision, LOD and LOQ. A linearity was established in the concentration range of 0.5-150% with coefficient of correlation 0.9993. The limit of detection (LOD) was 0.005 mu g/ml and the limit of quantification (LOQ) was 0.01 mu g/ml. The method was successfully applied to the assay and in-vitro dissolution studies of daclatasvir dihydrochloride in tablet dosage form. It can be concluded that this method can be very helpful in the quality control estimation of daclatasvir dihydrochloride in different pharmaceutical products intended for hepatitis C infections.
7 October 2018
Journal Article
ASA. Saleem
A. Saleem
MNM.I. Nasiri
M.I. Nasiri
KZK. Zaheer
K. Zaheer
SAS. Anwer
S. Anwer
TAT. Ali
T. Ali
SNS.S.B. Naqvi
S.S.B. Naqvi
+2
About Me
I am a pharmaceutical sciences professional with nearly 15 years of experience across academia, research, and industry. My career spans teaching, pharmaceutical research, and drug development, underpinned by a strong foundation in both practical and theoretical knowledge of the field.
Currently, I work as a Research Associate focused on X-ray diffraction (XRD) analysis of pancreatic cancer tissues , contributing to advanced translational oncology research. I am nearly finishing my PhD at Ulster University, where my research concentrated on formulation development and targeted drug delivery of antimicrobial agents using biomaterials. This work builds on a long-standing commitment to improving pharmaceutical outcomes through innovative research. My academic background includes a Pharm-D (2010), an MPhil in Pharmacy (2016), and a PhD near completion in Pharmaceutical Sciences. I have worked extensively in areas including pharmacy practice, pharmaceutical equivalence, formulation development, and pharmaceutics. Teaching has been an integral part of my journey. I have taught modules such as Pharmaceutical Technology, Industrial Pharmacy, and Pharmaceutical Biotechnology, and served as a PhD Demonstrator at Ulster University. My professional interests lie at the interface of drug delivery, formulation science, and translational medicine and diagnostics for cancer. I am driven by a passion for advancing pharmaceutical research that has real-world clinical impact.
Social Links
